Schrodinger Molecular Modeling Software Licenses

This is a combined synopsis/solicitation for Commercial Items prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 13.5, Test Program for Certain Commercial Items, as supplemented with additional information included in this announcement. This solicitation incorporates provisions and clauses in effect in the March 2005 FAR Revision, including all FAR Circulars issued as of the date of this synopsis. It is the intent of the National Library of Medicine (NLM) to procure licenses from Schrodinger, LLC, 101 SW Main Street, Suite 1300, Portland, Oregon 97204, on a sole source basis for Schrodinger brand name molecular modeling software products and support for a 12-month period of 07-01-13 through 06-30-14. NLM is processing this requirement for the Center for Information Technology (CIT), National Institutes of Health (NIH). This requirement includes the following Schrodinger brand name software licenses and interchangeable tokens, including support, for the 12-month period of 07-01-13 through 06-30-14: - 6 Floating Licenses for Prime - 1 Floating License for PIPER - 25 Floating Licenses for MacroModel and Jaguar - 24 Floating Licenses for Glide - 25 Interchangeable Tokens to be used with Library for Prime, Glide, XP Vis, Canvas, CoreHopping, CombiGlide, Phase, Liaison, QSite, MacroModel (includes ConfGen), Jaguar (includes pKa), PrimeX, QikProp, LigPrep, Epik, Strike, KNIME, MCPro+ and SiteMap In order to continue providing expert support to the NIH research community, CIT requires the continued use of commercially available molecular modeling software products for the specified 12-month period that provide all of the following functionalities: (1) a powerful and innovative software application for accurate protein structure predictions; (2) a fully-integrated protein structure program that provides an easy-to-use interface that takes a novice user intuitively from sequence to alignment to refined structure; (3) the ability to provide the expert user complete control over calculational settings to maximize accuracy of predictions; (4) a powerful and complete tool for generating accurate receptor models for structure-based drug design; (5) the ability to combine leading force fields, accurate effective solvation models, and advanced conformational searching methods that provide the most complete molecular modeling package suitable for a wide array of research; (6) a complete solution for ligand-receptor docking which provides the full spectrum of speed and accuracy from high-throughput virtual screening of millions of compounds to extremely accurate binding mode predictions with consistently high enrichment at every level; and (7) the ability of the software products to work with each other to simulate receptor flexibility in response to ligand-binding events. After consulting with NIH researchers, particularly from the National Cancer Institute (NCI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), CIT has determined that the Schrodinger software products are the only commercially available ones that can provide the required combination of comprehensive molecular modeling functionalities described above that are required by NIH researchers. This notice of intent is not a Request for Quotations (RFQ), nor is an RFQ available. However, all responsible and responsive sources may submit descriptive literature fully documenting their molecular modeling software applications and support which will be considered by the agency. Sources interested in responding to this notice must be able to provide software and support that can fulfill all of the requirements specified above. Information received in a timely manner will be considered solely for the purpose of determining whether to conduct a competitive procurement. A determination by the Government to conduct a competition for this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. This requirement is being processed for CIT by the National Library of Medicine (NLM). NLM intends to make an award for these commercial items in accordance with FAR Subpart 13.5, Test Program for Certain Commercial Items. The following clauses and provisions apply to this acquisition and may be obtained from the web site http://rcb.cancer.gov/rcb-internet/SAP/sap.htm: FAR 52.212-1, Instructions to Offerors; 52.212-3, Offeror's Representations and Certifications; 52.212-4, Contract Terms and Conditions, and FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes. The contractor shall comply with all other applicable Federal, state, and local laws, executive orders, rules and regulations in effect at time of award. Full text of FAR clauses and provisions are available at: http://www.arnet.gov/far/index.html. Responses must be received by the NLM Point of Contact within seventeen (17) calendar days from the publication date of this notice. NLM Synopsis No. NIH-LM-2013751 shall be noted on all correspondence to this announcement. RESPONSES SHALL BE SENT VIA EMAIL TO: Karen Miller, Contracting Officer at karen.miller@nih.gov. Inquiries regarding this notice may be made to Karen Miller (301) 435-4376 Fax 301 402-8169.